DK14283D0 - Fremgangsmade til fremstilling af ethere af ascorbinsyre og dermed beslaegtede forbindelser - Google Patents
Fremgangsmade til fremstilling af ethere af ascorbinsyre og dermed beslaegtede forbindelserInfo
- Publication number
- DK14283D0 DK14283D0 DK0142/83A DK14283A DK14283D0 DK 14283 D0 DK14283 D0 DK 14283D0 DK 0142/83 A DK0142/83 A DK 0142/83A DK 14283 A DK14283 A DK 14283A DK 14283 D0 DK14283 D0 DK 14283D0
- Authority
- DK
- Denmark
- Prior art keywords
- ethers
- procedure
- preparation
- ascorbic acid
- related compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33934482A | 1982-01-15 | 1982-01-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK14283D0 true DK14283D0 (da) | 1983-01-14 |
DK14283A DK14283A (da) | 1983-07-16 |
Family
ID=23328588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14283A DK14283A (da) | 1982-01-15 | 1983-01-14 | Fremgangsmaade til fremstilling af ethere af ascorbinsyre og dermed beslaegtede forbindelser |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0086554A1 (da) |
JP (1) | JPS58131978A (da) |
KR (1) | KR840003247A (da) |
AU (1) | AU1035183A (da) |
CA (1) | CA1181078A (da) |
DD (1) | DD209455A5 (da) |
DK (1) | DK14283A (da) |
ES (2) | ES8403118A1 (da) |
FI (1) | FI830078L (da) |
GB (1) | GB2114571A (da) |
GR (1) | GR77897B (da) |
IL (1) | IL67646A0 (da) |
PL (1) | PL240125A1 (da) |
PT (1) | PT76083B (da) |
RO (1) | RO86439B (da) |
ZA (1) | ZA83173B (da) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552895A (en) * | 1983-03-14 | 1985-11-12 | Eli Lilly And Company | Furo[3,2-b]furan-2-(3H)-ones |
JPS6058973A (ja) * | 1983-09-13 | 1985-04-05 | Mitsubishi Yuka Yakuhin Kk | γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤 |
JPS60130582A (ja) * | 1983-12-19 | 1985-07-12 | Takeda Chem Ind Ltd | 食品用酸化防止剤,アスコルビン酸誘導体およびその製造法 |
WO1986006720A1 (en) * | 1985-05-17 | 1986-11-20 | Takeda Chemical Industries, Ltd. | Ascorbic acid derivatives, production thereof, and pharmaceutical preparation therefrom |
WO1986007592A1 (en) * | 1985-06-18 | 1986-12-31 | Takeda Chemical Industries, Ltd. | Ascorbic acid derivatives, process for their preparation, and preparations containing same |
JPS60139619A (ja) * | 1983-12-27 | 1985-07-24 | Mutsuyuki Kochi | O−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤 |
JP2515556B2 (ja) * | 1986-08-29 | 1996-07-10 | 武田薬品工業株式会社 | ヒドロキシブテノライド誘導体およびその製造法 |
JP2752080B2 (ja) * | 1988-03-09 | 1998-05-18 | 株式会社日本ハイポックス | アスコルビン酸誘導体及びその製造方法並びにアスコルビン酸誘導体からなる抗酸化剤 |
JPH0730066B2 (ja) * | 1988-03-09 | 1995-04-05 | 株式会社日本ハイポックス | アスコルビン酸誘導体及びアスコルビン酸誘導体からなる抗酸化剤 |
DE68927904T2 (de) | 1988-09-01 | 1997-09-04 | Takeda Chemical Industries Ltd | Fumagillol-Derivate |
WO1991003471A1 (fr) * | 1989-09-11 | 1991-03-21 | Nippon Hypox Laboratories Incorporated | Derives d'acide ascorbique |
US5095126A (en) * | 1990-01-12 | 1992-03-10 | Ohio State University Research Foundation | Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids |
ATE125814T1 (de) * | 1990-03-07 | 1995-08-15 | Hoffmann La Roche | Verfahren zur herstellung von derivaten der ascorbinsäure. |
US5270336A (en) * | 1990-03-16 | 1993-12-14 | Merrell Dow Pharmaceuticals Inc. | Ascorbic acid derivatives |
EP0446539A1 (en) * | 1990-03-16 | 1991-09-18 | Merrell Dow Pharmaceuticals Inc. | Novel ascorbic acid derivatives |
JPH0429989A (ja) * | 1990-05-24 | 1992-01-31 | Nisshin Flour Milling Co Ltd | L―アスコルビン酸誘導体の製造法 |
GB9026114D0 (en) * | 1990-11-30 | 1991-01-16 | Norsk Hydro As | New compounds |
GB9201274D0 (en) * | 1992-01-21 | 1992-03-11 | Norsk Hydro As | New compounds |
GB9201275D0 (en) * | 1992-01-21 | 1992-03-11 | Norsk Hydro As | New compounds |
TW325997B (en) * | 1993-02-02 | 1998-02-01 | Senju Pharma Co | Pharmaceutical composition for preventing and treating retinal diseases |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
JP2002513391A (ja) | 1996-11-05 | 2002-05-08 | ザ チルドレンズ メディカル センター コーポレイション | 血管形成の抑制のための方法と組成物 |
EP0875246A1 (en) * | 1997-04-04 | 1998-11-04 | Showa Denko Kabushiki Kaisha | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer |
CA2324306C (en) * | 1998-03-27 | 2005-05-24 | Lg Chemical Ltd. | Polyethoxylated ascorbic acid derivatives as a novel antioxidant and process for preparing thereof |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
AU2001230554A1 (en) * | 2000-02-01 | 2001-08-14 | Mutsuyuki Kochi | Neovascularization inhibitory compositions and method of inhibiting neovascularization |
CZ20023231A3 (cs) * | 2000-03-31 | 2003-01-15 | Angiogene Pharmaceuticals Ltd. | Farmaceutické prostředky obsahující činidla poąkozující cévy |
ES2261458T3 (es) * | 2001-07-26 | 2006-11-16 | Tagra Biotechnologies Ltd | Derivados estabilizados del aciddo ascorbico 3-fosfato. |
KR100971599B1 (ko) | 2002-05-15 | 2010-07-20 | 비에이취엔 가부시끼가이샤 | 혈관 관련 질환의 예방 또는 치료를 위한 조성물 |
EP1939192A1 (en) * | 2006-12-28 | 2008-07-02 | Neuropharma S.A. | Cyclopentanone derivatives, method of synthesis and uses thereof |
FR2955493B1 (fr) * | 2010-01-28 | 2012-02-24 | Oreal | Utilisation de derives d'acide ascorbique en coloration des fibres keratiniques humaines, composition les comprenant, procede de coloration et dispositif |
JP5602456B2 (ja) * | 2010-02-24 | 2014-10-08 | 日本精化株式会社 | アスコルビン酸誘導体 |
US9550744B2 (en) * | 2013-09-25 | 2017-01-24 | University Of Florida Research Foundation, Inc. | Vitamin C prodrugs and uses thereof |
US10105407B2 (en) * | 2015-06-09 | 2018-10-23 | John P. Crow, JR. | Methods of extraction of nitrosylated or nitrated derivatives of ascorbic acid from myriciaria dubia and methods of synthesis thereof |
US10583171B2 (en) | 2015-11-30 | 2020-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | NMDAR antagonists for the treatment of diseases associated with angiogenesis |
-
1983
- 1983-01-10 IL IL67646A patent/IL67646A0/xx unknown
- 1983-01-10 RO RO109663A patent/RO86439B/ro unknown
- 1983-01-10 FI FI830078A patent/FI830078L/fi not_active Application Discontinuation
- 1983-01-11 ZA ZA83173A patent/ZA83173B/xx unknown
- 1983-01-11 CA CA000419220A patent/CA1181078A/en not_active Expired
- 1983-01-11 PT PT76083A patent/PT76083B/pt unknown
- 1983-01-12 DD DD83247195A patent/DD209455A5/de unknown
- 1983-01-12 PL PL24012583A patent/PL240125A1/xx unknown
- 1983-01-13 EP EP83300174A patent/EP0086554A1/en not_active Ceased
- 1983-01-13 GB GB08300907A patent/GB2114571A/en not_active Withdrawn
- 1983-01-13 JP JP58005144A patent/JPS58131978A/ja active Pending
- 1983-01-13 GR GR70253A patent/GR77897B/el unknown
- 1983-01-13 ES ES518968A patent/ES8403118A1/es not_active Expired
- 1983-01-13 AU AU10351/83A patent/AU1035183A/en not_active Abandoned
- 1983-01-14 KR KR1019830000115A patent/KR840003247A/ko not_active Application Discontinuation
- 1983-01-14 DK DK14283A patent/DK14283A/da not_active Application Discontinuation
- 1983-08-30 ES ES525239A patent/ES525239A0/es active Granted
Also Published As
Publication number | Publication date |
---|---|
RO86439A (ro) | 1985-03-15 |
ES518968A0 (es) | 1984-03-01 |
GR77897B (da) | 1984-09-25 |
FI830078L (fi) | 1983-07-16 |
KR840003247A (ko) | 1984-08-20 |
DD209455A5 (de) | 1984-05-09 |
FI830078A0 (fi) | 1983-01-10 |
DK14283A (da) | 1983-07-16 |
AU1035183A (en) | 1983-07-21 |
GB2114571A (en) | 1983-08-24 |
ES8502698A1 (es) | 1985-01-16 |
GB8300907D0 (en) | 1983-02-16 |
EP0086554A1 (en) | 1983-08-24 |
ES525239A0 (es) | 1985-01-16 |
ZA83173B (en) | 1984-08-29 |
PT76083A (en) | 1983-02-01 |
ES8403118A1 (es) | 1984-03-01 |
CA1181078A (en) | 1985-01-15 |
JPS58131978A (ja) | 1983-08-06 |
IL67646A0 (en) | 1983-05-15 |
PT76083B (en) | 1986-01-09 |
PL240125A1 (en) | 1984-04-24 |
RO86439B (ro) | 1985-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK14283D0 (da) | Fremgangsmade til fremstilling af ethere af ascorbinsyre og dermed beslaegtede forbindelser | |
DK1183D0 (da) | Fremgangsmade til fremstilling af tiazolidinderivater | |
DK424383D0 (da) | Fremgangsmade til fremstilling af doseringsenheder af cisplatin(ii)diamindichlorid | |
DK158820C (da) | Fremgangsmaade til fremstilling af vandingsroer | |
DK372283D0 (da) | Fremgangsmade til fremstilling af desoxyuridinderivater | |
DK544483D0 (da) | Fremgangsmade til fremstilling af blandede alkoholer | |
DK32383D0 (da) | Phosphinsyrederivater og fremgangsmade til fremstilling af disse | |
DK160869C (da) | Analogifremgangsmaade til fremstilling af substituerede urinstoffer og thiourinstoffer | |
DK271083A (da) | Praeparat til visualisering af blodlegemer | |
DK413481A (da) | Fremgangsmaade til fremstilling af carboxylalkylpeptider og thioet here og ethere deraf | |
DK309783A (da) | Fremgangsmaade til fremstilling af organoglykosider | |
DK280285D0 (da) | Fremgangsmaade til fremstilling af ascorbinsyre | |
DK119083D0 (da) | Fremgangsmade til fremstilling af alkanoylpyridinoner | |
DK159057C (da) | Fremgangsmaade til fremstilling af traespaanplader indeholdende formaldehydabsorbent og hydrofoberingsmiddel | |
DK75683A (da) | Fremgangsmaade til fremstilling af phosphorholdige antibiotiske forbindelser betegnet cl 1565-a, cl 1565-b og cl 1565-t | |
DK149944C (da) | Polymert dispergeringsmiddel og fremgangsmaader til fremstilling af samme | |
DK185683D0 (da) | Fremgangsmade til fremstilling af pleuromutilinderivater | |
DK424083A (da) | Fremgangsmaade til fremstilling af anthracyclinglycosider | |
DK316084D0 (da) | Fremgangsmaade til fremstilling af phenol-aldehyd-baserede harpiksagtige termohaerdnende polyoler | |
DK129983A (da) | 2-beta-d-ribofuranosylselenazol-4-carboxamidforbindelser og fremgangsmaader til fremstilling deraf | |
DK296383D0 (da) | Fremgangsmade til fremstilling af fenaetylaminer | |
DK62283D0 (da) | Fremgangsmade til fremstilling af peptidergotalkaloider | |
DK219483A (da) | Fremgangsmaade til fremstilling af anthracyclinglycosider | |
DK152051C (da) | Fremgangsmaade til fremstilling af krystallinsk natriumcefoperazon | |
DK519183A (da) | Fremgangsmaade til fremstilling af oxazolinoazetidinon-forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ATS | Application withdrawn |